Skip to main content

G7 Dual Mobility With Vivacit-E or Longevity PMCF

Enrolling by invitation · Not applicable · NCT05548972

Conditions: Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis, Dislocation, Hip, Femoral Neck Fractures, Trochanteric Fractures, Revision Surgeries

At a glance

Research payments reported, 2025
$103,381
U.S. investigators named
5
Sites paid
5
Planned or actual enrollment
358

About the trial

Sponsor
Zimmer Biomet
Tested
G7 Dual Mobility with Vivacit-E bearing (device), G7 Dual Mobility Longevity bearing (device)
Dates
Started 2023-03-20; completion 2037-08
Results posted
Not yet

This study is a global, multi-center, prospective, non-controlled, non-randomized, post-market clinical follow-up study. The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System when used with the Vivacit-E or Longevity polyethylene hip bearing and instrumentation in primary total and revision (total) hip arthroplasty

From ClinicalTrials.gov, last updated 2025-06-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Zimmer Biomet Holdings, Inc. reported $103,381 in research payments for this study in 2025 (19 payments).

Products named: G7

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.